Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s41232-020-00134-7 http://scihub22266oqcxt.onion/10.1186/s41232-020-00134-7 33024459!7533147!33024459     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Inflamm+Regen 2020 ; 40 (ä): 24 Nephropedia Template TP {{tp|p=33024459|t=2020. Outlook of IL-6 signaling blockade for COVID-19 pneumonia |pdf=|usr=}}{{33024459}} gab.com Text Outlook of IL-6 signaling blockade for COVID-19 pneumonia JO: Inflamm Regen http://www.kidney.de/pget.php?&tw=1&pmid=33024459 #FOAvip In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia. Given physiological roles of IL-6 in inflammatory conditions and the data from real world, IL-6 signal inhibitors, along with standard of care (SOC) treatment, might provide efficacy, offering the potential to treat COVID-19 in hospitalized populations more effectively than current SOC alone. Therefore, on-going and planned randomized placebo-controlled studies in combination with SOC and other therapeutics to assess safety and efficacy of IL-6 signal inhibitors in hospitalized patients with severe COVID-19 pneumonia will be warranted to address the high unmet need and burden of disease in this severely ill population. Twit Text FOAVip Outlook of IL-6 signaling blockade for COVID-19 pneumonia ????Inflamm Regen http://www.kidney.de/pget.php?&tw=1&pmid=33024459 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33024459 #FOAvip English Wikipedia <ref>{{Cite pmid|33024459}}</ref> Outlook of IL-6 signaling blockade for COVID-19 pneumonia #MMPMID33024459 Hashizume M Inflamm Regen 2020[]; 40 (ä): 24 PMID33024459show ga In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia. Given physiological roles of IL-6 in inflammatory conditions and the data from real world, IL-6 signal inhibitors, along with standard of care (SOC) treatment, might provide efficacy, offering the potential to treat COVID-19 in hospitalized populations more effectively than current SOC alone. Therefore, on-going and planned randomized placebo-controlled studies in combination with SOC and other therapeutics to assess safety and efficacy of IL-6 signal inhibitors in hospitalized patients with severe COVID-19 pneumonia will be warranted to address the high unmet need and burden of disease in this severely ill population. äOutlook of IL-6 signaling blockade for COVID-19 pneumonia (epmc).pdf DeepDyve Pubget Overpricing